Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.62 |
| ▸ | PI4KA | P42356 | 2/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | AHCY | P23526 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23477272 | 0.85 | PI4KA (0.58) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20857302 | 0.85 | PI4KA (0.58) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22458549 | 0.82 | PI4KA (0.55) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27105320 | 0.81 | PI4KA (0.58) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14725434 | 0.77 | PDE4A (0.47) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14725435 | 0.77 | PDE4A (0.43) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL763699 | 0.77 | YTHDC1 (1.00) | YTHDC1ADORA3PDE4APDE4BPDE4C | |
| SCHEMBL14356547 | 0.77 | PI4KA (0.66) | YTHDC1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22571150 | 0.75 | CDK1 (0.70) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20041716 | 0.75 | YTHDC1 (0.66) | YTHDC1ADORA3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382943-A1 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | ST PHARM CO., LTD. (KR) | 2023-11-30 | — | — | US | disclosed |
| US-20230382943-A1 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | ST PHARM CO., LTD. (KR) | 2023-11-30 | — | — | US | disclosed |
| US-11203610-B2 | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2021-12-21 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | US | disclosed |
| US-20190185509-A1 | 2'2' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2019-06-20 | — | — | US | disclosed |
| US-20190185510-A1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2019-06-20 | — | — | US | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-9833455-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | SPACEFILL ENTERPRISES LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | YTHDC1 3832/4885PI4KA 123/4885PI4K2B 145/4885 |
| US-20230382943-A1 | OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS | RNGTT, RNMT, NSUN2 | YTHDC1 217/4885PI4KA 4647/4885PI4K2B 4427/4885 |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | YTHDC1 817/4885PI4KA 1912/4885PI4K2B 2811/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | YTHDC1 830/4885PI4KA 3182/4885PI4K2B 3890/4885 |
| US-20190185509-A1 | 2'2' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | STING1, CGAS, TBK1 | YTHDC1 2304/4885PI4KA 646/4885PI4K2B 390/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | YTHDC1 1013/4885PI4KA 1962/4885PI4K2B 2788/4885 |
| US-11203610-B2 | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | STING1, CGAS, IRF3 | YTHDC1 2754/4885PI4KA 414/4885PI4K2B 306/4885 |
| US-20190185510-A1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | STING1, CGAS, IRF3 | YTHDC1 2751/4885PI4KA 440/4885PI4K2B 313/4885 |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | YTHDC1 828/4885PI4KA 2697/4885PI4K2B 1830/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | YTHDC1 1013/4885PI4KA 1962/4885PI4K2B 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.